Fate Therapeutics (FATE) Other Non-Current Liabilities (2012 - 2026)

Fate Therapeutics has reported Other Non-Current Liabilities for 15 years, with the latest figure at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 755.06% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 million (up 755.06% YoY), and the FY2025 full-year result was $2.1 million, up 300.76% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $2.1 million, roughly flat from $2.1 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $9.9 million in Q2 2022, with the low at $247000.0 in Q1 2025.
• Historically, Other Non-Current Liabilities has averaged $2.4 million across 5 years, with a median of $1.8 million in 2023.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities tumbled 92.7% — and 2026, when it surged 755.06%.
• Fate Therapeutics' Other Non-Current Liabilities stood at $3.9 million in 2022, then tumbled by 81.84% to $701000.0 in 2023, then slipped by 24.82% to $527000.0 in 2024, then jumped by 300.76% to $2.1 million in 2025, then changed by 0.0% to $2.1 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $2.1 million (Q1 2026), $2.1 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.